The estimated Net Worth of Michael A Friedman is at least $198 Thousand dollars as of 23 April 2019. Michael Friedman owns over 996 units of Mannkind Corp stock worth over $35,229 and over the last 20 years he sold MNKD stock worth over $0. In addition, he makes $162,691 as Independent Director at Mannkind Corp.
Michael has made over 41 trades of the Mannkind Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,159 units of MNKD stock worth $7,105 on 13 June 2019.
The largest trade he's ever made was exercising 56,116 units of Mannkind Corp stock on 3 October 2016 worth over $1,675,624. On average, Michael trades about 3,045 units every 28 days since 2004. As of 23 April 2019 he still owns at least 5,747 units of Mannkind Corp stock.
You can see the complete history of Michael Friedman stock trades at the bottom of the page.
Dr. Michael A. Friedman M.D. serves as Independent Director of the Company. In 2014, Dr. Friedman completed a decade of service as the President and Chief Executive Officer of the City of Hope National Medical Center. Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company. From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998. He joined the board of Celgene Corporation in February 2011 and the board of Smith & Nephew plc in April 2013. Dr. Friedman received a bachelor of arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School. The Board believes Dr. Friedman’s business experience, including his experience as an executive officer at biopharmaceutical companies and a leading clinical and research center specializing in cancer and diabetes, and his service at the Food and Drug Administration, combined with his business acumen and judgment provide our Board with valuable scientific and operational expertise and leadership skills.
As the Independent Director of Mannkind Corp, the total compensation of Michael Friedman at Mannkind Corp is $162,691. There are 15 executives at Mannkind Corp getting paid more, with Michael Castagna having the highest compensation of $1,551,760.
Michael Friedman is 76, he's been the Independent Director of Mannkind Corp since 2003. There are 1 older and 20 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.
Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens, and David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Mannkind Corp executives and other stock owners filed with the SEC include: